Stockscreener 앱 받기
9.46
8.60%
-0.89
시간 외 거래:
9.40
-0.06
-0.63%
전일 마감가:
$10.35
열려 있는:
$10
하루 거래량:
3.65M
Relative Volume:
1.26
시가총액:
$979.28M
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.7263
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
+0.11%
1개월 성능:
-1.25%
6개월 성능:
-52.98%
1년 성능:
-68.44%
1일 변동 폭
$9.4201
$10.10
1주일 범위
$8.855
$10.68
52주 변동 폭
$8.855
$31.10
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.46 | 979.28M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - Stockhouse Publishing
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
2025-03-10 | Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA | NDAQ:NTLA | Press Release - Stockhouse Publishing
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Intellia - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - GlobeNewswire Inc.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – NTLA - GlobeNewswire
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit ... - Bluefield Daily Telegraph
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Victoria Advocate
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Q1 Earnings Estimate for NTLA Issued By HC Wainwright - Defense World
Analysts Offer Predictions for NTLA FY2029 Earnings - MarketBeat
2025-03-06 | INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics | NDAQ:NTLA | Press Release - Stockhouse Publishing
HC Wainwright & Co. Initiates Coverage of Intellia Therapeutics (LSE:0JBU) with Buy Recommendation - Nasdaq
ROSEN, A TOP RANKED LAW FIRM, Encourages Intellia - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Intellia - GlobeNewswire
Investors who lost money with shares of Intellia Therapeutics, - openPR
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
H.C. Wainwright starts coverage on Intellia with 'buy' rating on optimism for heart disease therapies - TradingView
NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
HC Wainwright & Co. Initiates Coverage of Intellia Therapeutics (NTLA) with Buy Recommendation - Nasdaq
HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target -March 05, 2025 at 08:37 am EST - Marketscreener.com
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionNTLA - ACCESS Newswire
Intellia Therapeutics officer sells shares worth $6,104 - Investing.com
Intellia Therapeutics EVP James Basta sells $23,122 in stock - Investing.com
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Expands Team: What the New Employee Stock Grants Mean for Investors - StockTitan
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Markets Insider
Stock Market Recap: Intellia Therapeutics Inc (NTLA) Concludes at 9.45, a -6.34 Surge/Decline - The Dwinnex
Intellia stock touches 52-week low at $8.91 amid biotech slump - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.com - Defense World
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
Truist cuts Intellia stock target to $50, maintains Buy rating By Investing.com - Investing.com UK
Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating - Marketscreener.com
Intellia Therapeutics price target lowered to $50 from $90 at Truist - TipRanks
2025-03-03 | NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:NTLA | Press Release - Stockhouse Publishing
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
NASDAQ:NTLA Lawsuit Alert: Investors Who Purchased Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Should Contact the Shareholders Foundation - Newswire
Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $14.00 - Defense World
Intellia Therapeutics’ (NTLA) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Chardan Capital Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $68.00 - Defense World
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Intellia Therapeutics’ Earnings Call: Progress and Challenges - MSN
2025-03-02 | Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class ActionNTLA | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress (NASDAQ:NTLA) - Seeking Alpha
Earnings Release: Here's Why Analysts Cut Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target To US$46.08 - Simply Wall St
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.97%
자본화:
|
볼륨(24시간):